While Some New Agents Will Achieve Strong Sales, the Migraine Drug Market Will Decline $1.3 Billion by 2018 as Generic Erosion Takes Toll on Top-Selling Brands

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although sales of emerging therapies will partially offset losses to generic competitors, the migraine dr...

Smoking more than 5 cigarettes a day provokes migraine attacks

Tobacco acts as a precipitating factor for headaches, specifically migraines. This is indicated in a study which shows that smokers have more migraine attacks and that smoking more than five cigarettes a day triggers this headache. The work has appeared in the Journal of Headache and Pain . Th...

Common migraine pain condition also prevalent in cluster headache

(PHILADELPHIA) A pain condition common in people with migraines also has a high prevalence in patients with cluster headache, according to a study conducted by researchers at the Jefferson Headache Center at Jefferson Hospital for Neuroscience. Approximately half of a group of patients with clu...

Mayo Clinic Proceedings: The evolution of migraine from episodic headache to chronic disorder

ROCHESTER, Minn. -- Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings , are the basis for an ironic ...

Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder

ROCHESTER, Minn., May 26 /PRNewswire-USNewswire/ -- Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings...

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

- Both Rapid and Sustained Pain Relief for up to 48 Hours - - Conference Call to be Held Today at 8:30 a.m. ET - MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today that the efficacy portion of its first Phase 3 clinical t...

Clinical Topicals Makes Breakthrough Migraine Treatment Available Free to Soldiers

Soldiers Now Have New Weapon against Chronic Migraines from Post-Traumatic Stress Disorder NEW YORK, May 20 /PRNewswire/ -- Clinical Topicals PHP announced today that it is making its new migraine treatment available free to military personnel returning from service in Iraq and Afghanistan. ...

My Mother/Myself: Migraine Headaches are Hereditary

Experts urge sufferers to break the cycle of suffering 'Migraine Million' fundraiser honors one-in-a-million moms CHICAGO, April 23 /PRNewswire-USNewswire/ -- The mother/daughter relationship can give some women headaches -- literally. Yet, on Mother's Day we choose to put that aside an...

Safe exercise for migraine sufferers

Many patients who suffer from migraines avoid taking aerobic exercise because they are afraid that the physical activity may bring on a serious migraine attack. Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now developed an exercise programme that can improve fitne...

Study shows that exercise reduces migraine suffering

Gteborg, Sweden March 26, 2009 While physical exercise has been shown to trigger migraine headaches among sufferers, a new study describes an exercise program that is well tolerated by patients. The findings show that the program decreased the frequency of headaches and improved quality of life....

More>>

Migraine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

MOUNTAIN VIEW, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in patients with migraine headaches. AZ-104 is a lower-dose version of AZ-004 (Staccato loxap...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of mi...

Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disord...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

Company's End-of-Phase II Meeting with FDA Set for Sept. 29 LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to mee...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and Alan J. Tuchman, M.D. LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq:...

ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment

Top-line Data Show Significant Improvements With ROX-828 In Migraine Pain And Related Symptoms For Up to 48 Hours Vs. Placebo MENLO PARK, Calif., April 28 /PRNewswire/ -- ROXRO PHARMA, Inc. today announced positive top-line data from a clinical study of the company's novel investigatio...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5 and 5 mg Doses Compared to Placebo MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today positive top-line results from its 168 patient Ph...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

Initial Results Expected to be Reported in Q1 2008 PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has completed its target patient enrollment in its Phase 2a proof-of-concept clinical trial with AZ-104 (Stac...

Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in First Half of 2008 - LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose cli...

More>>

Migraine in Medical Products

Neuro-Cool™ Cool Head Wrap

Description:... The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
Company:Cincinnati Sub-Zero

Migraine in Medical Dictionary

Migraine

Migraine is a neurological syndrome characterized by altered bodily perceptions, severe headaches, and nausea. Physiologically, the migraine headache is a neurological condition more common to women than to men. The word... Learn about migraine headache including causes, symptoms, dia...

Mixed tension migraine

Mixed tension migraine . From Wikipedia, the free encyclopedia. Jump to: navigation, search ... Mixed tension migraines are also known as mixed migraines or ... Health Library > Health Encyclopedia > Mixed tension migraine . Printable Version ... People wi...

Common migraine

Migraine is a neurological syndrome characterized by altered bodily perceptions, severe headaches, and nausea. Physiologically, the migraine headache is a neurological condition more common to women than to men. The word... The presence of associated symptoms during a migraine attack ...

Classic migraine

Migraine is a neurological syndrome characterized by altered bodily perceptions, severe headaches, and nausea. Physiologically, the migraine headache is a neurological condition more common to women than to men. The word... Classic migraine information including symptoms, diagnosis, m...

Treatment

... treatment releases just a small amount of estrogen, ... Learn about migraine headache including symptoms such as intense throbbing pain ... What is the treatment for moderate to severe migraine headaches? ... Crime & Drug Abuse Treatment . Drug Testing. Drugg...

Sinus

... sinus , a vein collecting blood from the myocardium. Sinus venosus, a cavity in the heart of embryos ... 2.1 Sinus headache. 2.2 migraine misdiagnosis. 3 Predisposing factors. 3.1 Role of biofilms ... was the most common bacterial agent to cause sinus infections. ... Learn abou...

Scotoma

...on. Scintillating scotoma is the most common visual aura preceding migraine and was first described by 19th century physician Hubert Airy (1838–19...online dictionary with ... Prevent teichopsia, scintillating scotoma and migraine headache. ... SCOTOMA . DESCRIPTION: Portion(s) of the retinal field ...

Prodrome

...nset of a chronic neurological disorder such as migraine or... prodrome ( ) n. , pl. -dromes or -dro... aura and the prodrome . Check here for more on migraine symptoms ... What is prodrome ? Meaning of ...Library > Tables > Prodrome and aura in migraine and epilepsy ... ...

MRI of the head

...nets and ... through a patient to generate images, MRI imaging is based on the magnetic ... MRI of the head . FAQ: Answers to the top 75 migraine and headache questions ... An MRI of the head is a non-invasive procedure that uses powerful magnets and ... ...

Migraines

...about the various types and common treatments for migraine , a neurological disease which causes episodes o...severe to moderate headache ... Learn about migraine headache including causes, symptoms, diagnosis,...bout the different types of headaches including migraine , tension, cluster, menstrual, and spinal. Also fe...

More>>

Migraine in Biological News

Overuse of narcotics and barbiturates may make migraine worse

November 17, 2008 (Bronx, NY) A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks. This importan...

Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate

LA JOLLA, CA, June 20, 2008 A Webinar hosted by TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamat...

Concentrating on different aspects of pain leads to breakthrough in migraine genetics

Migraine is the most common cause of episodic headache, and by far the most common neurological cause of a doctors visit. It affects some 15% of the population, including some 41 million people in Europe, and places a considerable burden on healthcare in both the developed and the developing world...

Mice with a migraine show signs of brain damage

Migraines may be doing more than causing people skull-splitting pain. Scientists have found evidence that the headaches may also be acting like tiny transient strokes, leaving parts of the brain starved for oxygen and altering the brain in significant ways. A paper describing the work by neurosci...

Promising new drug targets identified for Huntington's disease

...ine in the journal Nature Chemical Biology, Professor Rubinsztein and colleagues have shown that a number of FDA-approved drugs for treatments such as migraine and hypertension are able to stimulate autophagy in fruit flies and zebrafish through unexpected pathways. "By screening a number of drugs that hav...

American Chemical Society's Weekly PressPac -- Sept. 26, 2007

... 2007 New tactics for trouncing those terrible migraine headaches Chemical & Engineering News Relief... from the pain, nausea and other awful symptoms of migraine could become just a sniff away, as researchers dev...istant editor Carmen Drahl describes potential new migraine medications that may be safer and more effective t...

Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage

... that intentionally combine caffeine and acetaminophen for the treatment of migraine headaches, menstrual discomfort and other conditions, the researchers say. ...h acetaminophen and caffeine, which are often used together as a remedy for migraine headaches, arthritis and other conditions. The researchers are currently...

Left-right wiring determined by neural communication in the embryonic worm

...nd Behavior at Rockefeller. "What is it that sets up this kind of handedness in the brain"" Prior studies had shown that a gene involved in human migraine headaches (an asymmetrical affliction) was involved in this decision, but something was happening earlier that researchers had yet to figure out. Barg...

Device effective in zapping the pain out of migraines

... An electronic device designed to "zap" away migraine pain before it starts may be the next form of reli...s are neural disturbances that signal the onset of migraine headaches. People who suffer from migraine headaches often describe "seeing" showers of shoot...

Scientists reveal how deadly toxin hijacks cells

...he ability of botox to act on a localized group of muscles, doctors have strategically used the toxin to treat an array of medical troubles, including migraine headaches, chronic inflammation and even stuttering. "I don't think there's a neuromuscular junction that hasn't been inhibited by injecting with boto...

Migraine in Biological Technology

Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System

SAN DIEGO, July 16 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Sumavel DosePro (sumatriptan injection) needle...

TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezam...

MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate ...

TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction

... company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is a...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

...petic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...

TorreyPines Receives Notice of Delisting from Nasdaq Global Market

... company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is a...

MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test

...rly diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunction, muscle weakness, gastrointestinal symptoms, migraine headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial genome test, MitoDx(TM), uses the revolutionary NextGen sequencing technology...

TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution

... company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is a...

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

...azine) and it has advanced AZ-104 ( Staccato loxapine) into Phase 2b testing. Both product candidates are being developed for the acute treatment of migraine headache. AZ-002 ( Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that hav...

Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors

...petic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...